Author(s) Details:
Khaled Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Roberto De Giorgio
Department of Translational Sciences, University of Ferrara, Ferrara, Italy.
Rami Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
This section is a part of the chapter: Pharmacological Ad-vancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review
Over the past two decades, significant advancements have been made in the development of effective and safer pharmacologic treatments for IBS-C. These advancements are grounded in an enhanced understanding of the pathophysiological mechanisms underlying IBS-C and the introduction of medications that demonstrate increased selectivity within established pharmacologic classes recognized for their efficacy.
This narrative review aims to provide a comprehensive overview of the available treatment options for IBS-C, highlighting their mechanisms of action, as well as their efficacy and safety profiles as determined by pertinent clinical trials. The review commences with a summary of laxative-based therapies and subsequently offers an up-to-date evaluation of four distinct classes of medications: prokinetics, prosecretory agents, bile acid modulators, and tenapanor.
How to Cite
Jadallah, K., Giorgio, R. D., & Jadallah, R. (2025). Pharmacological Advancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review. Medical Science: Trends and Innovations Vol. 4, 49–85. https://doi.org/10.9734/bpi/msti/v4/4177